Sheena Jonathan, co-founder of US-based genetic testing firm Natera Inc, has sold $410,825 (approximately £317,000) worth of company stock, according to a regulatory filing dated 18 July 2026. The transaction, conducted on the open market, reduces Jonathan's direct holdings but does not signal a change in her role at the company, which she helped establish.
Natera, listed on the Nasdaq under ticker NTRA, is a leader in non-invasive prenatal testing (NIPT) and liquid biopsy for cancer detection. The stock has seen significant swings this year, driven by regulatory updates in the US and reimbursement changes for genetic tests. As of 17 July, NTRA shares closed at $118.42, down roughly 12% year-to-date, reflecting broader headwinds in the precision medicine space.
For UK investors, the sale is a reminder of the risks tied to single-stock exposure in volatile biotech. Many British pension funds and retail investors hold Natera indirectly through US-focused exchange-traded funds (ETFs) such as the iShares Nasdaq Biotechnology ETF (IBB) or the ARK Genomic Revolution ETF (ARKG). The latter has Natera as a top-10 holding, meaning insider moves can influence short-term sentiment.
Analysts at Jefferies noted in a recent report that insider sales by founders are not uncommon after lock-up periods or vesting events, and do not necessarily indicate a bearish outlook. However, they added that the timing—amid a sector-wide downturn—could weigh on investor confidence. The FTSE 100 edged up 0.3% on 18 July, but the broader healthcare sector on the London Stock Exchange remained flat, with investors cautious ahead of US Federal Reserve policy signals.
Natera is scheduled to report its next quarterly earnings in early August 2026. UK shareholders should monitor whether the company's revenue growth—driven by its Signatera cancer test—meets consensus estimates. Any miss could amplify selling pressure, while a strong beat might offset the insider sale's impact.